← Leaderboards
Joseph A Califano
Johns Hopkins University
$16,242,638
Attributed
$19,939,937
Total exposure
20
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,936,492 · 21
By mechanism
R01$13,471,916 · 8
P30$5,174,901 · 2
R21$1,459,600 · 2
R44$1,021,347 · 1
P20$939,247 · 2
RC1$918,199 · 1
Top collaborators
- Elizabeth Jane Franzmann6 shared
- Andrew B. Sharabi3 shared
- Eric T Ahrens2 shared
- Xi Steven Chen1 shared
- Xinbin Gu1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Daria A Gaykalova$2,179,372
- Evgeny (eugene) G Izumchenko$1,669,074
- Nishant Agrawal$4,719,309
- Gypsyamber D'souza$25,879,984
- Johanna Lucy Hannan$992,857
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBaseIncidenceHuman PapillomavirusValidationDetectionTumorResponseRecurrenceHead And Neck Squamous Cell CarcinomaDesignGenomicsAreaLaboratoriesMalignant Oropharynx NeoplasmUnited StatesEnvironmentSalivaryClinical TrialsHead And Neck CancerDiagnosisAffectMeasurementCancer Patient
Grant awards (56)
Development of an effective, low-cost, point-of-care early detection test for oral cancer in low resource settings$1,021,347
R44 · FY2025 · CA
Enhancing Dendritic Cell Migration to Draining Sentinel Nodes to Improve Immunotherapy Response in HPV negative HNSCC$699,929
R01 · FY2025 · CA · contact PI
Optimizing immunoradiotherapy for HNSCC$663,994
R01 · FY2025 · CA · contact PI
Imaging tumor-associated macrophages in head and neck squamous cell carcinoma using fluorine-19 MRI$655,698
R01 · FY2025 · CA
Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer$619,487
R01 · FY2025 · CA · contact PI
Otolaryngology Training in Immunology, Virology and Molecular Biology$269,243
R25 · FY2025 · DC · contact PI
Imaging tumor-associated macrophages in head and neck squamous cell carcinoma using fluorine-19 MRI$655,700
R01 · FY2024 · CA
Optimizing immunoradiotherapy for HNSCC$632,764
R01 · FY2024 · CA · contact PI
Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer$589,762
R01 · FY2024 · CA · contact PI
Optimizing immunoradiotherapy for HNSCC$692,235
R01 · FY2023 · CA · contact PI
Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer$644,774
R01 · FY2023 · CA · contact PI
Plasma and saliva biomarkers of disease status in HPV related oropharynx cancer$260,710
R01 · FY2023 · CA · contact PI
Structural and Functional Genomics$28,304
P30 · FY2023 · CA · contact PI
Specialized Cancer Center Support Grant$4,996,555
P30 · FY2022 · CA · contact PI
Plasma and saliva biomarkers of disease status in HPV related oropharynx cancer$391,469
R01 · FY2022 · CA · contact PI
Structural and Functional Genomics$26,439
P30 · FY2022 · CA · contact PI
A novel point of care test for oral and oropharyngeal cancer risk$530,862
R01 · FY2021 · CA · contact PI
Plasma and saliva biomarkers of disease status in HPV related oropharynx cancer$400,118
R01 · FY2021 · CA · contact PI
Structural and Functional Genomics$28,289
P30 · FY2021 · CA · contact PI
A novel point of care test for oral and oropharyngeal cancer risk$512,031
R01 · FY2020 · CA · contact PI
Plasma and saliva biomarkers of disease status in HPV related oropharynx cancer$400,268
R01 · FY2020 · CA · contact PI
Optimizing an assay for high risk HPV DNA in body fluids$345,551
UH3 · FY2020 · CA · contact PI
Structural and Functional Genomics$67,114
P30 · FY2020 · CA · contact PI
A novel point of care test for oral and oropharyngeal cancer risk$488,480
R01 · FY2019 · CA · contact PI
Plasma and saliva biomarkers of disease status in HPV related oropharynx cancer$387,831
R01 · FY2019 · CA · contact PI
Optimizing an assay for high risk HPV DNA in body fluids$338,661
UH3 · FY2019 · CA · contact PI
Structural and Functional Genomics$28,200
P30 · FY2019 · CA · contact PI
A novel point of care test for oral and oropharyngeal cancer risk$554,293
R01 · FY2018 · CA · contact PI
Optimizing an assay for high risk HPV DNA in body fluids$270,302
UH2 · FY2018 · CA · contact PI
A novel point of care test for oral and oropharyngeal cancer risk$593,922
R01 · FY2017 · CA · contact PI
Epigenetic Biomarker Discovery in HPV Related HNSCC$368,125
R01 · FY2017 · DE · contact PI
Optimizing an assay for high risk HPV DNA in body fluids$128,218
UH2 · FY2017 · CA · contact PI
Education and Training Pilot Project$61,613
P20 · FY2017 · CA · contact PI
Epigenetic Biomarker Discovery in HPV Related HNSCC$368,125
R01 · FY2016 · DE · contact PI
Education and Training Pilot Project$53,206
P20 · FY2016 · CA · contact PI
Howard University Summer Research Experience Program in Oral Health Disparity for Underrepresented Racial and Ethnic Students$52,823
R25 · FY2016 · DE
Epigenetic Biomarker Discovery in HPV Related HNSCC$211,567
R01 · FY2015 · DE · contact PI
Epigenetic Biomarker Discovery in HPV related HNSCC$163,628
R01 · FY2015 · DE · contact PI
Education and Training Pilot Project$51,956
P20 · FY2015 · CA · contact PI
Epigenetic Biomarker Discovery in HPV related HNSCC$384,750
R01 · FY2014 · DE · contact PI
Epigenetic Biomarker Discovery in HPV related HNSCC$384,750
R01 · FY2013 · DE · contact PI
Integrative Pathway Analysis of Epigenomic/transcriptional Alteration in HNSCC$461,215
RC1 · FY2010 · DE · contact PI
Tadalafil Induced Modulation of Immune Response in HNSCC$360,800
R21 · FY2010 · CA · contact PI
Validation of epigenetic biomarkers of head and neck cancer progression--OLD$265,486
RC2 · FY2010 · DE · contact PI
Integrative Pathway Analysis of Eqigenomic/transcriptional Alteration in HNSCC$456,984
RC1 · FY2009 · DE · contact PI
Cetuximab for Treatment of High-risk Pre-malignant Upper Aerodigestive Lesions$369,000
R21 · FY2009 · CA · contact PI
Tadalafil Induced Modulation of Immune Response in HNSCC$360,800
R21 · FY2009 · CA · contact PI
Validation of epigenetic biomarkers of head and neck cancer progression--OLD$280,998
RC2 · FY2009 · DE · contact PI
Cetuximab for Treatment of High-risk Pre-malignant Upper Aerodigestive Lesions$369,000
R21 · FY2008 · CA · contact PI
HU/JHU Head and Neck Cancer Translational Research and *$189,864
P20 · FY2008 · CA · contact PI
HU/JHU Head and Neck Cancer Translational Research and *$189,864
P20 · FY2007 · CA · contact PI
Molecular Anatomy of Mitochondria in HNSC$399,144
R01 · FY2006 · DE · contact PI
HU/JHU Head and Neck Cancer Translational Research and *$195,534
P20 · FY2006 · CA · contact PI
Molecular Anatomy of Mitochondria in HNSC$408,750
R01 · FY2005 · DE
HU/JHU Head and Neck Cancer Translational Research and *$197,210
P20 · FY2005 · CA
Molecular Anatomy of Mitochondria in HNSC$408,750
R01 · FY2004 · DE